[Pregnancy and systemic lupus erythematosus].
BACKGROUND
The interrelations between systemic lupus erythematosus (SLE) and pregnancy are reason for debate. Patients with SLE may present antiphospholipid antibodies (APL), anti-Ro (a-Ro) or anti-La (a-La) with their influence in pregnancy not being well defined.


METHODS
The pregnancies in a series of 96 fertile age women with SLE, followed during the period of 1975-1991 with a mean follow up of 6.2 years were studied. The spontaneous or provoked abortions, prematurity and the number of flares of the disease during pregnancy and during the year after birth were analyzed. The number of flares was compared with that presented by a control group of women with SLE of similar clinical features followed over the same time period.


RESULTS
Twenty-seven patients had 35 pregnancies with 23 full term pregnancies, 5 spontaneous abortions and 7 provoked abortions. Twenty-six percent of the deliveries were premature. One or two flares related with 43% of the pregnancies with viable fetus (11 flares in total) were registered. The number of flares in the control group was 6%. The difference was not statistically significant (p = 0.55) but the relative risk was of 1.6. No relation was found between the presence of APL, a-Ro and a-La and the course of the pregnancy. No case of lupus neonatorum was observed.


CONCLUSIONS
Pregnancy is not advised in patients with systemic lupus erythematosus in remission. Patients should be more frequently controlled during pregnancy and post partum. The presence of antiphospholipid antibodies or anti-Ro does not modifies the prognosis.
Moga Sampere
I
I
Servicio de Medicina Interna, Hospital de Bellvitge-Prínceps d'Espanya, Barcelona.
Formiga Pérez
F
F
Canet González
R
R
Pac Ferraz
M
M
Mitjavila Villero
F
F
Fernández-Nogués
F
F
D000028:Abortion, Induced / Q000706:statistics & numerical data; D000022:Abortion, Spontaneous / Q000453:epidemiology / Q000276:immunology; D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000097:blood; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000453:epidemiology / Q000276:immunology*; D008181:Lupus Nephritis / Q000453:epidemiology / Q000276:immunology; D016017:Odds Ratio; D010298:Parity; D011247:Pregnancy; D011248:Pregnancy Complications / Q000453:epidemiology / Q000276:immunology*; D011379:Prognosis
D017152:Antibodies, Antiphospholipid
Embarazo y lupus eritematoso sistémico.